Potent inhibition of CYP2D6 by haloperidol metabolites

Stereoselective inhibition by reduced haloperidol

Jae Gook Shin, Khadidjatou Kane, David A. Flockhart

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Aims: We evaluated the inhibitory effect of haloperidol and its metabolites on CYP2D6 activity in order to better understand the potential role of these metabolites in drug interactions involving haloperidol. Methods: The inhibitory effects of haloperidol and five of its metabolites on dextrorphan formation from dextromethorphan, a marker probe of CYP2D6 activity, were measured in human liver microsomal preparations. Apparent kinetic parameters for enzyme inhibition were determined by nonlinear regression analysis of the data. Results: Racemic reduced haloperidol and its metabolite, RHPTP competitively inhibited dextromethorphan O-demethylation with estimated Ki values (0.24 μM and 0.09 μM, respectively) that were substantially lower than that of haloperidol (0.89 μM). The inhibitory effect of S(-)-reduced haloperidol was more potent than the R(+)-enantiomer, with estimated Ki values of 0.11 μM and 1.1 μM, respectively. The pyridinium metabolite of haloperidol, HPP+ inhibited the enzyme activity noncompetitively with a Ki value of 0.79 μM. The N-dealkylated metabolites of haloperidol (FBPA and CPHP) had a diminished inhibitory potency. While FBPA showed no notable inhibitory effect on dextrorphan formation, CPHP showed moderate competitive inhibition with a Ki value of 20.9 μM. Conclusions: The principal metabolites of haloperidol inhibit CYP2D6, suggesting that they might contribute to the inhibitory effects of the drug. Reduced haloperidol seems to inhibit CYP2D6 activity in an enantioselective manner with the physiologically occurring S(-) enantiomer being more potent.

Original languageEnglish (US)
Pages (from-to)45-52
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume51
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP2D6
Haloperidol
Dextrorphan
Dextromethorphan
Enzymes
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Drug Interactions
Regression Analysis
Liver
Pharmaceutical Preparations

Keywords

  • CYP2D6
  • Enantiomer
  • Haloperidol
  • Inhibition
  • Interaction
  • Metabolites
  • Reduced haloperidol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Potent inhibition of CYP2D6 by haloperidol metabolites : Stereoselective inhibition by reduced haloperidol. / Shin, Jae Gook; Kane, Khadidjatou; Flockhart, David A.

In: British Journal of Clinical Pharmacology, Vol. 51, No. 1, 2001, p. 45-52.

Research output: Contribution to journalArticle

Shin, Jae Gook ; Kane, Khadidjatou ; Flockhart, David A. / Potent inhibition of CYP2D6 by haloperidol metabolites : Stereoselective inhibition by reduced haloperidol. In: British Journal of Clinical Pharmacology. 2001 ; Vol. 51, No. 1. pp. 45-52.
@article{f7a0644a4ac64c868fbd7fb577028e16,
title = "Potent inhibition of CYP2D6 by haloperidol metabolites: Stereoselective inhibition by reduced haloperidol",
abstract = "Aims: We evaluated the inhibitory effect of haloperidol and its metabolites on CYP2D6 activity in order to better understand the potential role of these metabolites in drug interactions involving haloperidol. Methods: The inhibitory effects of haloperidol and five of its metabolites on dextrorphan formation from dextromethorphan, a marker probe of CYP2D6 activity, were measured in human liver microsomal preparations. Apparent kinetic parameters for enzyme inhibition were determined by nonlinear regression analysis of the data. Results: Racemic reduced haloperidol and its metabolite, RHPTP competitively inhibited dextromethorphan O-demethylation with estimated Ki values (0.24 μM and 0.09 μM, respectively) that were substantially lower than that of haloperidol (0.89 μM). The inhibitory effect of S(-)-reduced haloperidol was more potent than the R(+)-enantiomer, with estimated Ki values of 0.11 μM and 1.1 μM, respectively. The pyridinium metabolite of haloperidol, HPP+ inhibited the enzyme activity noncompetitively with a Ki value of 0.79 μM. The N-dealkylated metabolites of haloperidol (FBPA and CPHP) had a diminished inhibitory potency. While FBPA showed no notable inhibitory effect on dextrorphan formation, CPHP showed moderate competitive inhibition with a Ki value of 20.9 μM. Conclusions: The principal metabolites of haloperidol inhibit CYP2D6, suggesting that they might contribute to the inhibitory effects of the drug. Reduced haloperidol seems to inhibit CYP2D6 activity in an enantioselective manner with the physiologically occurring S(-) enantiomer being more potent.",
keywords = "CYP2D6, Enantiomer, Haloperidol, Inhibition, Interaction, Metabolites, Reduced haloperidol",
author = "Shin, {Jae Gook} and Khadidjatou Kane and Flockhart, {David A.}",
year = "2001",
doi = "10.1046/j.1365-2125.2001.01313.x",
language = "English (US)",
volume = "51",
pages = "45--52",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Potent inhibition of CYP2D6 by haloperidol metabolites

T2 - Stereoselective inhibition by reduced haloperidol

AU - Shin, Jae Gook

AU - Kane, Khadidjatou

AU - Flockhart, David A.

PY - 2001

Y1 - 2001

N2 - Aims: We evaluated the inhibitory effect of haloperidol and its metabolites on CYP2D6 activity in order to better understand the potential role of these metabolites in drug interactions involving haloperidol. Methods: The inhibitory effects of haloperidol and five of its metabolites on dextrorphan formation from dextromethorphan, a marker probe of CYP2D6 activity, were measured in human liver microsomal preparations. Apparent kinetic parameters for enzyme inhibition were determined by nonlinear regression analysis of the data. Results: Racemic reduced haloperidol and its metabolite, RHPTP competitively inhibited dextromethorphan O-demethylation with estimated Ki values (0.24 μM and 0.09 μM, respectively) that were substantially lower than that of haloperidol (0.89 μM). The inhibitory effect of S(-)-reduced haloperidol was more potent than the R(+)-enantiomer, with estimated Ki values of 0.11 μM and 1.1 μM, respectively. The pyridinium metabolite of haloperidol, HPP+ inhibited the enzyme activity noncompetitively with a Ki value of 0.79 μM. The N-dealkylated metabolites of haloperidol (FBPA and CPHP) had a diminished inhibitory potency. While FBPA showed no notable inhibitory effect on dextrorphan formation, CPHP showed moderate competitive inhibition with a Ki value of 20.9 μM. Conclusions: The principal metabolites of haloperidol inhibit CYP2D6, suggesting that they might contribute to the inhibitory effects of the drug. Reduced haloperidol seems to inhibit CYP2D6 activity in an enantioselective manner with the physiologically occurring S(-) enantiomer being more potent.

AB - Aims: We evaluated the inhibitory effect of haloperidol and its metabolites on CYP2D6 activity in order to better understand the potential role of these metabolites in drug interactions involving haloperidol. Methods: The inhibitory effects of haloperidol and five of its metabolites on dextrorphan formation from dextromethorphan, a marker probe of CYP2D6 activity, were measured in human liver microsomal preparations. Apparent kinetic parameters for enzyme inhibition were determined by nonlinear regression analysis of the data. Results: Racemic reduced haloperidol and its metabolite, RHPTP competitively inhibited dextromethorphan O-demethylation with estimated Ki values (0.24 μM and 0.09 μM, respectively) that were substantially lower than that of haloperidol (0.89 μM). The inhibitory effect of S(-)-reduced haloperidol was more potent than the R(+)-enantiomer, with estimated Ki values of 0.11 μM and 1.1 μM, respectively. The pyridinium metabolite of haloperidol, HPP+ inhibited the enzyme activity noncompetitively with a Ki value of 0.79 μM. The N-dealkylated metabolites of haloperidol (FBPA and CPHP) had a diminished inhibitory potency. While FBPA showed no notable inhibitory effect on dextrorphan formation, CPHP showed moderate competitive inhibition with a Ki value of 20.9 μM. Conclusions: The principal metabolites of haloperidol inhibit CYP2D6, suggesting that they might contribute to the inhibitory effects of the drug. Reduced haloperidol seems to inhibit CYP2D6 activity in an enantioselective manner with the physiologically occurring S(-) enantiomer being more potent.

KW - CYP2D6

KW - Enantiomer

KW - Haloperidol

KW - Inhibition

KW - Interaction

KW - Metabolites

KW - Reduced haloperidol

UR - http://www.scopus.com/inward/record.url?scp=0035142516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035142516&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2125.2001.01313.x

DO - 10.1046/j.1365-2125.2001.01313.x

M3 - Article

VL - 51

SP - 45

EP - 52

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 1

ER -